Altered placental methyl donor transport in the dexamethasone programmed rat

Citation for published version:
https://doi.org/10.1016/j.placenta.2011.12.017

Digital Object Identifier (DOI):
10.1016/j.placenta.2011.12.017

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Placenta

Publisher Rights Statement:
Copyright 2012 Elsevier Ltd.
Short communication

Altered placental methyl donor transport in the dexamethasone programmed rat

C.S. Wyrwoll, D. Kerrigan, M.C. Holmes, J.R. Seckl, A.J. Drake*

Endocrinology Unit, Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK

A R T I C L E   I N F O

Article history:
Accepted 21 December 2011

Keywords:
Early life programming
Epigenetics
Methyl donors
DNA methylation

A B S T R A C T

There is increasing evidence for a role for epigenetic modifications in early life ‘programming’ effects. Altered placental methyl donor transport may impact on the establishment of epigenetic marks in the fetus. This study investigated the effects of prenatal glucocorticoid overexposure on placental methyl donor transport. Glucocorticoids increased folate but decreased choline transport and reduced fetal plasma methionine levels. There was no change in global DNA methylation in fetal liver. These data suggest prenatal glucocorticoid overexposure causes complex alterations in the placental transport of key methyl donors which may have important implications for maternal diet and nutrient supplementation in pregnancy.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

The association between exposure to an adverse early life environment and increased cardiometabolic disease risk has led to the development of the early life origins hypothesis [1]. Potential mechanisms include altered maternal/fetal nutrition [2,3] and prenatal glucocorticoid overexposure [4]. We have developed a rat model of ‘programming’ by fetal glucocorticoid overexposure in which prenatal exposure to a synthetic glucocorticoid, dexamethasone (Dex) reduces birthweight and leads to insulin resistance and hypertension in adulthood [4]. Maternal stress or inhibition of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2, the placental ‘barrier’ to maternal physiological glucocorticoids) results in similar effects on offspring phenotype [5]. Increased fetal glucocorticoid overexposure may also be important in humans. The efficiency of placental 11β-HSD2 near term varies considerably in humans [6] and the lowest placental 11β-HSD2 activity is seen in babies with the smallest birth weights, suggesting increased fetal exposure to maternal glucocorticoids [6]. Additionally, exogenous glucocorticoids which readily cross the placenta are used in obstetric practice to accelerate lung maturation in fetuses at risk of congenital adrenal hyperplasia. Finally, placental 11β-HSD2 is not a complete barrier to glucocorticoids, so that increased circulating levels in the mother may result in increased fetal exposure; indeed maternal antenatal stress/anxiety has been associated with programming effects in the offspring [8,9].

Recent evidence suggests early life programming effects may be mediated by epigenetic modifications including DNA methylation and histone marks [10,11]. The availability of methyl donors such as choline, methionine and folate acid during fetal development can influence the establishment of epigenetic modifications in the fetus [11–14]. Alterations in placental nutrient transport have been described in animal models of programming including prenatal glucocorticoid overexposure [15,16]. The purpose of this study was to explore the effects of prenatal glucocorticoid overexposure on the placental transport of methyl donors. This was achieved via characterization of placental methyl donor transport and gene expression; plasma methionine levels and DNA methylation levels in fetal liver.

2. Methods

2.1. Animals

Virgin female Wistar rats (200–250 g; Harlan UK) maintained under conditions of controlled lighting and temperature (22 °C) were time-mated and injected subcutaneously with 100 μg/kg Dex or vehicle (Veh) from embryonic day (E) 15–19 as described [4]. Eight females per group were culled at E20. All studies were conducted under licensed approval by the UK Home Office, under the Animals (Scientific Procedures) Act, 1986, and with local ethical committee approval. Maternal and fetal plasma (pooled from one litter) was stored at −20 °C. Placental labyrinth was stored at −80 °C.

2.2. Placental transport of methyl donors at E20

Placental transport of choline, folic acid or methionine was measured using modified methods [17]. 8–10 pregnant rats were anaesthetized and 300 μl PBS containing 3.5 μCi of 14C-choline chloride, 14C-methionine or 1H-folic acid (American Radiolabelled Chemicals (UK) Ltd.) injected intravenously. Animals were killed and fetuses and placentas weighed after 7 min (a timepoint found in preliminary experiments to be on the linear scale of placental transfer). Fetuses were lysed overnight at 55 °C in Biosol (National Diagnostics, UK). Radioactive counts (Tri-Carb 2100TR; Packard, UK) in each fetus were used to calculate the amount of radioisotope transferred/g placenta (a measure of placental transfer), or per gram of fetus (a
measure of the amount of solute received by the fetus). Average values for fetuses within a litter were used to calculate a mean for all litters.

2.3. Quantification of mRNA by real-time PCR

Total RNA was extracted from placental labyrinth, reverse transcribed and real-time PCR performed as previously described [18] to analyse the expression of genes involved in folate and choline transport using predesigned assays from Applied Biosystems, UK (Folate receptor (FR): Rn00591759_m1; Reduced folate carrier (RFC): Rn00446220_m1; Organic cation transporter 1 (OCT1): Rn00562250_m1; Organic cation transporter 3 (OCT3): Rn00580082_m1). Results were corrected for the expression of cyclophilin A (Rn00690933_m1).

2.4. Plasma methionine levels

Plasma methionine levels were measured by the Biochemistry Department, Royal Hospital for Sick Children, Edinburgh, UK using a Biochrom 30 amino acid analyser (Biochrom Ltd, Cambridge, UK).

2.5. Genome-wide DNA methylation

Our previous studies have shown altered expression and DNA methylation of specific genes in fetal liver [19]. In order to determine whether these changes reflected global alterations in DNA methylation, DNA was prepared from fetal liver by phenol-chloroform extraction and global cytosine methylation measured as previously described [20].

2.6. Statistical analysis

Data were analysed by independent Student t testing and are expressed as mean ± SEM, with each litter representing n = 1.

3. Results and discussion

Prenatal Dex reduced fetal weight at E20 (Dex 2.16 ± 0.03 vs Veh 2.34 ± 0.02 g; p < 0.0001). We found opposite effects of
glucocorticoid exposure on placental choline and folate transport. The placental transport capacity of choline was reduced (39%; $P < 0.001$) by Dex, such that the fetus received less choline per gram fetal weight (55% less than Veh fetuses; $P < 0.001$; Fig. 1A). In contrast, Dex increased placental folate transport by 2.5 times ($P < 0.05$) such that the Dex-exposed fetuses received 2.3 times more folate per gram fetal weight ($P < 0.05$; Fig. 1B). The reason for these changes remain to be determined as we found no changes in mRNA levels of the folate transporters RFC and FR or the choline transporters OCT1 and OCT3 in the placental labyrinth (Fig. 2).

Placental methionine transport (Fig. 1C) and maternal plasma methionine concentrations were unaffected by Dex (Dex 37.4 +/- 1.9 vs Veh 41.5 +/- 1.8 μmol/l; $p = 0.18$), however Dex exposure reduced fetal plasma methionine levels (Dex 69.8 +/- 7.1 μmol/l vs Veh 99.8 +/- 2.6 μmol/l; $p < 0.01$). There are complex interactions between choline, folate and methionine [21–24] with the folate and choline metabolic pathways meeting at the conversion of homocysteine to methionine and because of this, altered metabolism of one methyl donor can result in compensatory changes in another [25]. For instance, administration of a choline de restriction [11] so that methyl donor supplementation has been proposed as one strategy to reduce the consequences associated with exposure to an adverse intrauterine environment. However, these data suggest that methyl donor supply is complex and that compensatory mechanisms may operate if deficiency occurs, highlighting the necessity for further studies to determine optimal interventions to reduce disease risk.

In conclusion, we show that glucocorticoid overexposure in pregnancy changes placental transport of folate and choline and reduces fetal plasma methionine levels. Changes in these key components of the methyl donor cycle may have implications for disease risk in the offspring. Given the intricate inter-relationships between the components of the methyl donor cycle, our findings illustrate the subtle complexities of the mechanisms which must be resolved before any appropriately targeted therapies can be devised.

References


Fig. 2. mRNA expression of placental transporters involved in the transport of folate: Folate receptor (FR), Reduced Folate Carrier (RFC) and choline: Oct1 and Oct3. N = 15 Dex placentas from 10 litters and 12 vehicle placentas from 8 litters. Values are mean ± SEM.
tissue and increased hepatic lipid accumulation but not obesity on a high-fat diet. Endocrinology 2010;151:1581–7.


